Literature DB >> 15731042

Citrobacter rodentium lifA/efa1 is essential for colonic colonization and crypt cell hyperplasia in vivo.

Jan-Michael A Klapproth1, Maiko Sasaki, Melanie Sherman, Brian Babbin, Michael S Donnenberg, Paula J Fernandes, Isabel C A Scaletsky, Daniel Kalman, Asma Nusrat, Ifor R Williams.   

Abstract

Previously, we have identified a large gene (lifA, for lymphocyte inhibitory factor A) in enteropathogenic Escherichia coli (EPEC) encoding a protein termed lymphostatin that suppresses cytokine expression in vitro. This protein also functions as an adhesion factor for enterohemorrhagic E. coli (EHEC) and Shiga toxin-producing E. coli and is alternatively known as efa1 (EHEC factor for adherence 1). The lifA/efa1 gene is also present in Citrobacter rodentium, an enteric pathogen that causes a disease termed transmissible murine colonic hyperplasia (TMCH), which induces colitis and massive crypt cell proliferation, in mice. To determine if lifA/efa1 is required for C. rodentium-induced colonic pathology in vivo, three in-frame mutations were generated, disrupting the glycosyltransferase (GlM12) and protease (PrMC31) motifs and a domain in between that does not encode any known activity (EID3). In contrast to infection with wild-type C. rodentium, that with any of the lifA/efa1 mutant strains did not induce weight loss or TMCH. Enteric infection with motif mutants GlM12 and PrM31 resulted in significantly reduced colonization counts during the entire 20-day course of infection. In contrast, EID3 was indistinguishable from the wild type during the initial colonic colonization, but cleared rapidly after day 8 of the infection. The colonic epithelium of all infected mice displayed increased epithelial regeneration. However, significantly increased regeneration was observed by day 20 only in mice infected with the wild-type in comparison to those infected with lifA/efa1 mutant EID3. In summary, lifA/efa1 is a critical gene outside the locus for enterocyte effacement that regulates bacterial colonization, crypt cell proliferation, and epithelial cell regeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731042      PMCID: PMC1064951          DOI: 10.1128/IAI.73.3.1441-1451.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways.

Authors:  J Celli; M Olivier; B B Finlay
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  Identification of a novel genetic locus that is required for in vitro adhesion of a clinical isolate of enterohaemorrhagic Escherichia coli to epithelial cells.

Authors:  L Nicholls; T H Grant; R M Robins-Browne
Journal:  Mol Microbiol       Date:  2000-01       Impact factor: 3.501

3.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products.

Authors:  K A Datsenko; B L Wanner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Citrobacter rodentium, the causative agent of transmissible murine colonic hyperplasia, exhibits clonality: synonymy of C. rodentium and mouse-pathogenic Escherichia coli.

Authors:  S A Luperchio; J V Newman; C A Dangler; M D Schrenzel; D J Brenner; A G Steigerwalt; D B Schauer
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

5.  Citrobacter rodentium espB is necessary for signal transduction and for infection of laboratory mice.

Authors:  J V Newman; B A Zabel; S S Jha; D B Schauer
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease.

Authors:  L M Higgins; G Frankel; G Douce; G Dougan; T T MacDonald
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens.

Authors:  K Tani; W J Murphy; O Chertov; R Salcedo; C Y Koh; I Utsunomiya; S Funakoshi; O Asai; S H Herrmann; J M Wang; L W Kwak; J J Oppenheim
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

8.  A large toxin from pathogenic Escherichia coli strains that inhibits lymphocyte activation.

Authors:  J M Klapproth; I C Scaletsky; B P McNamara; L C Lai; C Malstrom; S P James; M S Donnenberg
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection.

Authors:  D Czerucka; S Dahan; B Mograbi; B Rossi; P Rampal
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Characterization of the catalytic domain of Clostridium novyi alpha-toxin.

Authors:  C Busch; K Schömig; F Hofmann; K Aktories
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

View more
  31 in total

1.  Quantitative proteomic analysis of type III secretome of enteropathogenic Escherichia coli reveals an expanded effector repertoire for attaching/effacing bacterial pathogens.

Authors:  Wanyin Deng; Hong B Yu; Carmen L de Hoog; Nikolay Stoynov; Yuling Li; Leonard J Foster; B Brett Finlay
Journal:  Mol Cell Proteomics       Date:  2012-06-01       Impact factor: 5.911

2.  Bacillus subtilis-mediated protection from Citrobacter rodentium-associated enteric disease requires espH and functional flagella.

Authors:  Sara E Jones; Katherine L Knight
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 3.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

4.  Atypical Enteropathogenic Escherichia coli: from Kittens to Humans and Beyond!

Authors:  Shantanu Bhatt
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

5.  Mutational Analysis of the Chlamydia muridarum Plasticity Zone.

Authors:  Krithika Rajaram; Amanda M Giebel; Evelyn Toh; Shuai Hu; Jasmine H Newman; Sandra G Morrison; Laszlo Kari; Richard P Morrison; David E Nelson
Journal:  Infect Immun       Date:  2015-05-04       Impact factor: 3.441

6.  Prevalence and characteristics of the O122 pathogenicity island in typical and atypical enteropathogenic Escherichia coli strains.

Authors:  Mônica A M Vieira; Fábia A Salvador; Rosa M Silva; Kinue Irino; Tânia M I Vaz; Anna C Rockstroh; Beatriz E C Guth; Tânia A T Gomes
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

Review 7.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 8.  In vitro and in vivo model systems for studying enteropathogenic Escherichia coli infections.

Authors:  Robyn J Law; Lihi Gur-Arie; Ilan Rosenshine; B Brett Finlay
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

9.  Distribution of pathogenicity islands OI-122, OI-43/48, and OI-57 and a high-pathogenicity island in Shiga toxin-producing Escherichia coli.

Authors:  Wenting Ju; Jinling Shen; Magaly Toro; Shaohua Zhao; Jianghong Meng
Journal:  Appl Environ Microbiol       Date:  2013-03-22       Impact factor: 4.792

10.  Increased adherence and expression of virulence genes in a lineage of Escherichia coli O157:H7 commonly associated with human infections.

Authors:  Galeb S Abu-Ali; Lindsey M Ouellette; Scott T Henderson; David W Lacher; James T Riordan; Thomas S Whittam; Shannon D Manning
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.